Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016
Published Oct 26, 2016
74 pages — Published Oct 26, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016, provides in depth analysis on Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted pipeline therapeutics.

The report provides comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategie

  
Source:
Document ID
GMDHC0610TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Overview71
Therapeutics Development83
  Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Stage of Development81
  Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Therapy Area91
  Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Indication101
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Products under Development by Companies132
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Companies Involved in Therapeutics Development216
  Alteogen Inc.211
  Chengdu Kanghong Pharmaceuticals Group Co Ltd221
  Clearside BioMedical, Inc.231
  Formycon AG241
  Regeneron Pharmaceuticals Inc251
  ThromboGenics NV261
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drug Profiles2732
  (aflibercept + nesvacumab) Drug Profile271
  (aflibercept + rinucumab) Drug Profile282
  (aflibercept + triamcinolone acetonide) Drug Profile303
  aflibercept Drug Profile3312
  aflibercept biosimilar Drug Profile451
  aflibercept biosimilar Drug Profile461
  conbercept Drug Profile472
  SL-186 Drug Profile491
  SL-188 Drug Profile501
  TG-931 Drug Profile511
  THR-317 Drug Profile523
  ziv-aflibercept Drug Profile554
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Dormant Projects591
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Discontinued Products601
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Featured News &Press Releases6112
  Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting611
  Sep 30, 2016: Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration611
  Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS621
  Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion631
  Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists guidance641
  May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection651
  May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma651
  Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion661
  Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403671
  Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven681
  Feb 29, 2016: Formycon discloses details on second pipeline product FYB203 is a biosimilar for Eylea (aflibercept)681
  Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403691
  Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration701
  Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization701
  Sep 25, 2015: Bayer s Eye Drug Recommended for EU Approval in Fifth Indication712
Appendix732
  Methodology731
  Coverage731
  Secondary Research731
  Primary Research731
  Expert Panel Validation731
  Contact Us731
  Disclaimer741

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Placenta-Growth-Factor-Vascular-Endothelial-Growth-Factor-Related-Protein-or-PGF-Pipeline-Review-H2-2016-2088-16891>
  
APA:
Global Markets Direct - Market Research. (2016). Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Placenta-Growth-Factor-Vascular-Endothelial-Growth-Factor-Related-Protein-or-PGF-Pipeline-Review-H2-2016-2088-16891>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.